Some of the questions just pop in my mind.
Do we really have to do marketing now? What's the ROI for marketing expenditures at this stage?
Do we have enough financial resources for that? How much should we be spending on marketing?
Do we have clients/customers/patients/product & services on the market?
If marketing were only good for the sake of share price in the short-term gains and doesn't have any long term value, what's the point then?
To say we didn't do much about marketing is also not true. In fact, people tend to forget we have done a great deal of SCIENCE MARKETING.
(Check out from the company website - Presentation/Video, Media and ASX announcement sections.)
Just look at those science-related activities here:
1) Publishing in academic/medical journals
2) Presenting at scientific and professional conferences, printed brochures.. etc
3) Our relationship with researchers and scientific community in their field of research
4) Developing partnerships/collaboration with academia
Based on the above, this will build our company image, reputation and trustworthiness of the company.
Don't forget we have ongoing engagement with DMD communities... PPMD, Duchene Parent Project in Europe (https://www.duchenne-spain.org/atl1102/), Key Opinion Leaders, investors etc..... Again, don't underestimate those webinars, the podcast with Mike Ham (target US audience) etc
Trust the Management Board, when the time is right, they will do plenty of Generic Marketing.
People tend to criticise the Management Board because your expectations were not met in a timely manner just doesn't make sense at all.
I personally think that for those people keep on complains, they just portray themselves as a victim.
- Forums
- ASX - By Stock
- For General Information
Some of the questions just pop in my mind.Do we really have to...
-
- There are more pages in this discussion • 3,219 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PER (ASX) to my watchlist
|
|||||
Last
8.7¢ |
Change
0.003(3.57%) |
Mkt cap ! $78.43M |
Open | High | Low | Value | Volume |
8.4¢ | 8.7¢ | 8.4¢ | $72.99K | 855.8K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 452608 | 8.4¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
8.7¢ | 398595 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 452608 | 0.084 |
3 | 212500 | 0.083 |
2 | 106250 | 0.080 |
2 | 125578 | 0.079 |
1 | 12462 | 0.078 |
Price($) | Vol. | No. |
---|---|---|
0.087 | 398595 | 1 |
0.088 | 400000 | 1 |
0.089 | 135000 | 2 |
0.090 | 794374 | 5 |
0.092 | 50000 | 1 |
Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
Featured News
PER (ASX) Chart |
The Watchlist
CCO
THE CALMER CO INTERNATIONAL LIMITED
Anthony Noble, MD & CEO
Anthony Noble
MD & CEO
Previous Video
Next Video
SPONSORED BY The Market Online